Peptide Dosing Mistakes That Cause Overdoses

The FDA has reported instances of compounded GLP-1 patients administering doses 5 to 20 times their intended amount. In one case, 25 units were drawn instead of the intended 5. The frequency of such errors is increasing rapidly. FAERS recorded 9,800 incorrect tirzepatide dose reports in 2024, compared to 1,248 two years prior. Reports of additional dosing rose from 283 to 2,984 during the same period. U.S. poison centers received 159 calls related to GLP-1 in 2024, up from 32 in 2023.

These incidents are rarely due to atypical biological responses; arithmetic mistakes are generally to blame. Errors repeatedly mentioned on forums such as r/Peptides, r/Semaglutide, and r/tirzepatide can lead to serious consequences like ER visits, ICU admissions, and acute pancreatitis. Each mistake can be corrected prior to the next injection. For assistance with dosage calculations, the peptide dosage calculator and reconstitution calculator are available to perform the necessary mathematical checks.

A syringe unit indicates volume, not a specific drug amount. On a U-100 insulin syringe, one unit represents 0.01 mL. The milligrams delivered by this volume depend on the concentration of the vial. Drawing 20 units from a vial with a 2.5 mg/mL concentration results in a 0.5 mg dose, whereas drawing the same 20 units from a 5 mg/mL vial delivers 1 mg, twice the intended dose, with no visible difference in the syringe.

An endocrinologist quoted by Healthline mentioned patients who state "I use 50 units" without knowing the equivalent in milligrams. Units are meaningful only in conjunction with the recipe that produced them. Prioritize micrograms or milligrams over units consistently.

Syringe units correlate with the syringe type, not the drug. A U-100 syringe marks 0.01 mL per unit, whereas a U-40 syringe, commonly used for veterinary insulin, marks 0.025 mL per unit. Drawing to "10" on a U-40 results in 2.5 times the dose delivered by "10" on a U-100. The two syringe types appear almost identical, leading to potential errors.

This results in significant dosing discrepancies. A 250 mcg BPC-157 dose drawn with the incorrect syringe becomes 625 mcg. Stick to one syringe type, ensure it matches the vial, and recalculate the draw if either changes. The unit converter aids in translating doses across U-100, U-50, and U-40 syringes so the dosage aligns with the syringe used.

One milligram equals 1000 micrograms. Vial labels often use milligrams, while community dosing typically references micrograms. Failing to convert these units leads to a thousandfold error, not merely a ten percent discrepancy. Microdosing semaglutide at 0.05 to 0.125 mg can lead to such oversights due to the diminutive numbers involved.

A clear sign of this error is when a dosage calculation suggests an implausible volume, such as a 100 mL draw. Ensure both unit forms are visible: 250 mcg equals 0.25 mg.

Concentration is determined by milligrams divided by milliliters, meaning the amount of bacteriostatic water added establishes the vial's overall dose. Adding 1 mL of bacteriostatic water to a 10 mg retatrutide vial results in a 10 mg/mL concentration. Adding 2 mL reduces it to 5 mg/mL. The same powder yields different doses per draw until the vial is depleted.

To mitigate this, work backward. Input the vial size, target dose, and desired draw to calculate the required water volume. The reverse calculator suggests the necessary volume and alerts for awkward draws under 5 units, where minor errors can significantly alter doses. Verify the exact water amount before finalizing the vial preparation.

This issue frequently appears in reconstitution discussions. The draw number is calculated at mixing time, but the underlying information is often forgotten. Days later, only "draw 20" remains, making it impossible to verify the correct dose or match it to a new vial. Users often cannot remember whether it involved 5 mg in 2 mL or 10 mg in 1 mL, leading to a fourfold dosage error.

The solution requires minimal effort: document the full recipe on the vial and maintain it with the dose, so 20 units is 0.2 mL, which is 0.5 mg, derived from 5 mg in 2 mL, with a concentration of 2.5 mg/mL. A saved protocol in the planner retains the recipe alongside every reminder, ensuring the draw is never isolated.

Each new vial constitutes a new recipe. Different compounders, different milligrams, different water, and often different concentrations are involved. Using previously memorized units with a new vial can lead to overdoses. The FDA has highlighted that compounded semaglutide varies in concentration and unit labels, allowing a consistent draw across refills to unexpectedly double or halve the dose.

Treat each vial as distinct. Upon opening a new one, enter its fresh recipe and compare: if the previous vial was 2.5 mg/mL and the new one is 5 mg/mL, the draw for 0.5 mg changes from 20 units to 10. Avoid carrying over numbers from previous vials automatically.

Initial eagerness combined with packaging can cause this problem. Telehealth starter kits and gray-market vials often include 4 to 6 mg starter doses, exceeding the initial protective dose used in trials. Retatrutide trials initiate at 2 mg; kits offering 4 to 6 mg bypass this step, causing significant nausea on the first night.

The entry dose is not merely a precautionary measure; it mitigates side effects while the body adjusts. Begin with the trial-tested entry dose, even if the purchased vial is larger. The GLP-1 titration tool outlines the standard initiation protocol for semaglutide, tirzepatide, and retatrutide, ensuring the first step is appropriately sized.

Side effects tend to peak shortly after each dosage increase, rather than during the stable periods in between. Semaglutide-induced nausea occurs in approximately 15.8% of patients at 0.5 mg and rises to 44% at 2.4 mg. A case report associated rapid dose escalation with gastroparesis, a condition where the stomach becomes paralyzed and can persist beyond the drug's presence (PMC12497442).

Anxiety about reaching a plateau often prompts early escalation. The advisable approach is to maintain each tier for at least four weeks, only advancing once the current dosage is well-tolerated. Accelerating the process does not increase strength; it merely intensifies side effects prematurely.

Two timing errors share the misconception that higher doses equate to better results. Semaglutide trials show similar HbA1c outcomes for 1 mg and 2 mg doses, so increasing the dose in response to a weight plateau primarily results in more side effects, not improved efficacy. A plateau typically signifies adaptation rather than under-dosing.

The break scenario is less obvious. Gastrointestinal tolerance diminishes during a pause, whether due to supply issues, travel, or side effects. A 3 to 4 week hiatus can bring back initial nausea levels. Resuming at the previous maintenance dose can cause the body to react as if it's the initial dose. After a break, reduce the dose by one or two tiers and gradually increase again, rather than immediately returning to the former level.

A weekly injection occurs approximately 52 times annually, insufficient for it to become habitual. Compounded vials lack the audible confirmation of a pen click or the visual cue of an empty blister pack. Individuals then forget whether they have dosed, leading to an additional injection hours later, resulting in two doses within a 72-hour period. This scenario has resulted in ER visits, with FAERS noting an increase in extra-dose reports from 283 to 2,984.

The practice of doubling up doses to compensate is another issue. With drugs having a 5 to 7 day half-life, the impulse to "catch up" by taking a missed dose can stack on top of the existing dose. The specific guideline is: for semaglutide, administer the missed dose if it is within 5 days, otherwise skip it; for tirzepatide, the window is 4 days. Avoid double dosing and do not allow the next dose to fall within 72 hours of the last. Logging each injection immediately after administration eliminates uncertainty about whether a dose was taken.

Many peptides are administered in cycles, but the vial itself does not indicate when the cycle concludes. BPC-157 is often used for months beyond its typical 4 to 8 week cycle because of perceived ongoing benefits. Growth hormone secretagogues like ipamorelin and CJC-1295 lose effectiveness with continuous use due to receptor desensitization, and diminished results are often misinterpreted as a need for increased dosage rather than a break.

Track the start date and cycle length to ensure "week 6 of 8" is documented rather than assumed. When effects wane late in a cycle, increasing the dose seldom resolves the issue; taking a break typically does. Getting the dose right is only half the job: storage, sterility, and knowing which symptoms mean stop are covered in peptide storage, sourcing, and safety mistakes.